Modulation of Human Motor Cortex Excitability by Single Doses of Amantadine

[1]  U. Ziemann,et al.  The role of GABAB receptors in intracortical inhibition in the human motor cortex , 2006, Experimental Brain Research.

[2]  T. Arndt,et al.  Determination of serum amantadine by liquid chromatography-tandem mass spectrometry. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[3]  B. Pleger,et al.  The NMDA antagonist memantine affects training induced motor cortex plasticity – a study using transcranial magnetic stimulation [ISRCTN65784760] , 2005, BMC Neuroscience.

[4]  W. Oertel,et al.  Motor cortex excitability in focal epilepsies not including the primary motor area--a TMS study. , 2005, Brain : a journal of neurology.

[5]  Jon W. Johnson,et al.  Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block , 2005, Journal of Neuroscience.

[6]  Jean-Pascal Lefaucheur,et al.  Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of antiparkinsonian treatment and cortical stimulation , 2005, Clinical Neurophysiology.

[7]  W. Oertel,et al.  Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function—a TMS study , 2004, Epilepsy Research.

[8]  Zafiris J Daskalakis,et al.  Transcranial magnetic stimulation: a new investigational and treatment tool in psychiatry. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[9]  Janine Reis,et al.  Topiramate Selectively Decreases Intracortical Excitability in Human Motor Cortex , 2002, Epilepsia.

[10]  F. Fazio,et al.  New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET – [11C]raclopride study , 2002, Journal of Neural Transmission.

[11]  L. Cohen,et al.  Dual modulating effects of amphetamine on neuronal excitability and stimulation-induced plasticity in human motor cortex , 2002, Clinical Neurophysiology.

[12]  R. Lamb,et al.  Influenza A Virus M2 Ion Channel Activity Is Essential for Efficient Replication in Tissue Culture , 2002, Journal of Virology.

[13]  L. Cohen,et al.  Modulation of use‐dependent plasticity by d‐amphetamine , 2002, Supplements to Clinical neurophysiology.

[14]  P. Giacomini,et al.  Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study , 2001, Experimental Brain Research.

[15]  Robert Chen,et al.  Impairment of motor cortex activation and deactivation in Parkinson's disease , 2001, Clinical Neurophysiology.

[16]  W. Fischer,et al.  Riluzole suppresses motor cortex facilitation in correlation to its plasma level , 2000, Experimental Brain Research.

[17]  A Dagher,et al.  Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine , 1999, Synapse.

[18]  P. Schwenkreis,et al.  Influence of the N-methyl-d-aspartate antagonist memantine on human motor cortex excitability , 1999, Neuroscience Letters.

[19]  K J Werhahn,et al.  Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans , 1999, The Journal of physiology.

[20]  Walter Paulus,et al.  Complete suppression of voluntary motor drive during the silent period after transcranial magnetic stimulation , 1999, Experimental Brain Research.

[21]  M Hallett,et al.  Dextromethorphan decreases the excitability of the human motor cortex , 1998, Neurology.

[22]  B Conrad,et al.  Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia , 1998, Muscle & nerve.

[23]  L. Metman,et al.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease , 1998, Neurology.

[24]  J. Rothwell,et al.  Magnetic transcranial stimulation at intensities below active motor threshold activates intracortical inhibitory circuits , 1998, Experimental Brain Research.

[25]  W Paulus,et al.  Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. , 1997, Electroencephalography and clinical neurophysiology.

[26]  E. Albuquerque,et al.  Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. , 1997, The Journal of pharmacology and experimental therapeutics.

[27]  C. Schroeder,et al.  Different modes of inhibition by adamantane amine derivatives and natural polyamines of the functionally reconstituted influenza virus M2 proton channel protein. , 1997, The Journal of general virology.

[28]  H. Tsuji,et al.  Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. , 1997, The Journal of physiology.

[29]  Tetsuya Takahashi,et al.  Inhibitory Effect of MK-801 on Amantadine-Induced Dopamine Release in the Rat Striatum , 1996, Brain Research Bulletin.

[30]  B. Steinhoff,et al.  Effects of antiepileptic drugs on motor cortex excitability in humans: A transcranial magnetic stimulation study , 1996, Annals of neurology.

[31]  Walter Paulus,et al.  Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation , 1996, Neuroscience Letters.

[32]  Walter Paulus,et al.  The effect of lorazepam on the motor cortical excitability in man , 1996, Experimental Brain Research.

[33]  O. Krishtal,et al.  Comparative Patch‐clamp Studies with Freshly Dissociated Rat Hippocampal and Striatal Neurons on the NMDA Receptor Antagonistic Effects of Amantadine and Memantine , 1996, The European journal of neuroscience.

[34]  A. Berardelli,et al.  Cortical inhibition in Parkinson's disease. A study with paired magnetic stimulation. , 1996, Brain : a journal of neurology.

[35]  K. Jellinger,et al.  Therapeutic brain concentration of the NMDA receptor antagonist amantadine , 1995, Neuropharmacology.

[36]  Masatoshi Tanaka,et al.  Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism , 1994, Brain Research.

[37]  B. Northover.  Effect of pre-treating rat atria with potassium channel blocking drugs on the electrical and mechanical responses to phenylephrine. , 1994, Biochemical pharmacology.

[38]  N Accornero,et al.  Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. , 1994, Brain : a journal of neurology.

[39]  M. Hallett,et al.  Non-invasive differentiation of motor cortical representation of hand muscles by mapping of optimal current directions. , 1994, Electroencephalography and clinical neurophysiology.

[40]  J. Kornhuber,et al.  Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex , 1993, Neuroscience Letters.

[41]  C. Marsden,et al.  Corticocortical inhibition in human motor cortex. , 1993, The Journal of physiology.

[42]  R. Jackisch,et al.  Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. , 1992, Archives internationales de pharmacodynamie et de therapie.

[43]  C. Lücking,et al.  Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. , 1992, The Journal of pharmacology and experimental therapeutics.

[44]  J. C. Stoof,et al.  The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. , 1992, European journal of pharmacology.

[45]  M Hallett,et al.  Topographic mapping of the human motor cortex with magnetic stimulation: factors affecting accuracy and reproducibility. , 1992, Electroencephalography and clinical neurophysiology.

[46]  M. Hallett,et al.  Spinal motor neuron excitability during the silent period after cortical stimulation. , 1991, Electroencephalography and clinical neurophysiology.

[47]  J. Bormann,et al.  Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. , 1991, European journal of pharmacology.

[48]  H. Nakanishi,et al.  Enhancement of NMDA receptor-mediated synaptic potential evoked in rat medial-amygdala neuron following olfactory bulbectomy , 1990, Brain Research.

[49]  K. Shannon,et al.  Amantadine and motor fluctuations in chronic Parkinson's disease. , 1987, Clinical neuropharmacology.

[50]  C. W. Hess,et al.  Excitability of the human motor cortex is enhanced during REM sleep , 1987, Neuroscience Letters.

[51]  F. Aoki,et al.  Amantadine kinetics in healthy elderly men: Implications for influenza prevention , 1985, Clinical pharmacology and therapeutics.

[52]  F. Aoki,et al.  Amantadine kinetics in healthy young subjects after long‐term dosing , 1979, Clinical pharmacology and therapeutics.

[53]  G. Cohen,et al.  Evaluation of amantadine as a releasing agent or uptake blocker for H 3 -dopamine in rat brain slices. , 1972, European journal of pharmacology.

[54]  U. Ungerstedt,et al.  Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. , 1971, European journal of pharmacology.

[55]  R. C. Oldfield.  The assessment and analysis of handedness: the Edinburgh inventory. , 1971, Neuropsychologia.

[56]  V. G. Vernier,et al.  The toxicologic and pharmacologic properties of amantadine hydrochloride. , 1969, Toxicology and applied pharmacology.

[57]  R. Hornick,et al.  Studies on induced influenza in man. I. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against a2/Rockville/1/65 strain. , 1968, JAMA.

[58]  M. Tegenthoff,et al.  The glutamate antagonist Riluzole suppresses intracortical facilitation , 2005, Journal of Neural Transmission.

[59]  J. Doyon,et al.  Motor-learning Impairment by Amantadine in Healthy Volunteers , 2004, Neuropsychopharmacology.

[60]  M Hallett,et al.  Transcranial magnetic stimulation. Negative effects. , 1995, Advances in neurology.

[61]  M. Weller,et al.  Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis , 1993, Journal of neural transmission. Parkinson's disease and dementia section.